The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).
Pasi A. Janne
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis; Genentech; Merrimack Pharmaceuticals ; Pfizer; Sanofi
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - LabCorp
Suresh S. Ramalingam
Consultant or Advisory Role - AstraZeneca
James Chih-Hsin Yang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; InnoPharmax; Lilly; Novartis; Pfizer; Takeda
Honoraria - Abbott Laboratories; AstraZeneca; Bayer; Boehringer Ingelheim; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Myung-Ju Ahn
No relevant relationships to disclose
Dong-Wan Kim
No relevant relationships to disclose
Sang-We Kim
No relevant relationships to disclose
David Planchard
Consultant or Advisory Role - AstraZeneca
Yuichiro Ohe
Honoraria - AstraZeneca
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche
Claire Watkins
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Mireille Cantarini
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Serban Ghiorghiu
Employment or Leadership Position - AstraZeneca (B)
Stock Ownership - AstraZeneca (B)
Malcolm Ranson
Honoraria - AstraZeneca
Research Funding - AstraZeneca